Home/Filings/4/0001192482-06-000080
4//SEC Filing

Valera Pharmaceuticals Inc 4

Accession 0001192482-06-000080

CIK 0001305409operating

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 5:44 PM ET

Size

8.8 KB

Accession

0001192482-06-000080

Insider Transaction Report

Form 4
Period: 2006-02-07
Feldman Jerome I
Director10% Owner
Transactions
  • Conversion

    Common Stock

    2006-02-07$4.35/sh+404,004$1,757,4172,070,670 total(indirect: The reporting person is a principal of the entity which owns the subject shares.)
  • Conversion

    Series B Preferred Stock

    2006-02-07$0.72/sh2,068,966$1,500,0000 total(indirect: The reporting person is a principal of the entity which owns the subject shares.)
    Exercise: $4.35Common Stock (404,004 underlying)
Footnotes (4)
  • [F1]These shares are owned directly MXL Industries, Inc. for which Mr. Feldman serves as the Chief Executive Officer. MXL Industries, Inc. is a wholly-owned subsidiary of National Patent Development Corporation, a publicly held corporation for which Mr. Feldman serves as the Chairman of the Board and the Chief Executive Officer. By virtue of his offices in MXL Industries, Inc. and National Patent Development Corporation, Mr. Feldman may be deemed to own such shares beneficially. Mr. Feldman disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest in MXL industries, Inc. and National Patent Development Corporation.
  • [F2]These shares were immediately convertible upon their issuance.
  • [F3]None.
  • [F4]This number of shares represents the Common Stock Equivalent for the Preferred Stock indirectly owned by the reporting person as of February 6, 2006; it includes accrued but unpaid dividends and it reflects a 1:6 reverse stock split which occurred on the Issuer's Common Stock on January 27, 2006. The conversion rate of the Derivative Securities is equal to (i) the stated value of the Derivative Securities ($.725 per share) plus an amount equal to all accrued and unpaid dividends per share divided by (ii) the conversion price for such Derivative Securities.

Issuer

Valera Pharmaceuticals Inc

CIK 0001305409

Entity typeoperating

Related Parties

1
  • filerCIK 0001305409

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 5:44 PM ET
Size
8.8 KB